🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A patient and provider share updates on pelabresib plus Rituxan treatment, which met the MANIFEST-2 trial's primary end point for those with #myelofibrosis. Nature Medicine hubs.li/Q03qyw-T0

🔬 Multiple Myeloma RF shares key takeaways from Day 1 of the #ASCO25 Annual Meeting. Explore their latest blog to learn about promising updates on Blenrep, advances in treatment for newly diagnosed high-risk #myeloma patients, and more: hubs.li/Q03qyCwN0

Less than 2 weeks away! Don't miss CURE's first-ever Virtual Educated Patient® Updates in Metastatic Breast Cancer on June 16, where you'll hear from Dr. Igor Makhlin of Penn Medicine. Time: 7:30 PM ET Hosted by CURE Today | Outcomes4Me 👉Register! hubs.ly/Q03qvkCQ0

Rina-S Yields 50% Response Rate in Advanced Endometrial Cancer Karmanos Cancer Institute ASCO #ASCO25 #EndometrialCancer #gyncsm curetoday.com/view/rina-s-yi…

Nubeqa Combo Positively Impacts HRQoL vs Placebo in Prostate Cancer Subgroup Dana-Farber Harvard Medical School ASCO #ASCO25 #Oncology #ProstateCancer #pcsm curetoday.com/view/nubeqa-co…

Dealing with Insensitivity After Breast Cancer Surgery #BreastCancerAwareness #BreastCancer #bcsm curetoday.com/view/dealing-w…

Continuing Novel Therapeutic Research Presents New Options in Lung Cancer UNC Lineberger #LungCancer #MedTwitter curetoday.com/view/continuin…

New or Persistent Acid Reflux May Signal Esophageal Cancer Risk #Oncology #MedTwitter curetoday.com/view/new-or-pe…

Addressing Complications from ADT Therapy to Treat Prostate Cancer Alicia Morgans, MD, MPH Dana-Farber #ProstateCancer #pcsm #Oncology #MeddTwitter curetoday.com/view/addressin…

“Concentrate on learning the language of cancer.” @kelly_s_irvin has been living with stage 4 #ovariancancer for 9.5 years. In this powerful #ShareYourStory video, she reflects on what she would tell her newly diagnosed self.

🚨 New Research Alert from #ASCO25! A novel biotherapeutic, ATR04-484, is being evaluated in a trial for EGFR inhibitor-induced rashes—common, painful side effects that lead to treatment interruption. ASCO #LungCancer #lcsm #MedTwitter 🔗 Read more: hubs.li/Q03qMZqW0

The U.S. FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung cancer. #LungCancer #MedEd #lcsm Read more about the regularly acceptance here: hubs.li/Q03qN5Ds0

I jumped at the chance when Cure asked me to talk about what I've learned as an #ovariancancer patient coming up on a 10-year anniversary. Live life, advocate, be hopeful, use your time well! @thankscancer "I have a reason to be here."

Iopofosine-131 Earns U.S. FDA Breakthrough for #WaldenstromMacroglobulinemia Cellectar Biosciences hubs.li/Q03qVpg70

Columvi Combo Enhances Survival Outcomes in R/R Lymphoma Subgroup Mass General Cancer Center ASCO #ASCO25 #Oncology #Lymphoma #lcsm curetoday.com/view/columvi-c…

Being in the Present Moment With Multiple Myeloma #MultipleMyeloma #CancerSurvivor #mmsm curetoday.com/view/being-in-…

Understanding Supportive Care Needs in Younger Women With Cancer #Oncology @CityofHope hubs.li/Q03qZw6N0

A Unicorn Among Us Andrew Kuykendall MD Moffitt Cancer Center #Oncology #MedEd #MedTwitter curetoday.com/view/a-unicorn…

Radiation therapy can treat #LungCancer at all stages, easing symptoms, improving precision and minimizing side effects with modern techniques.Julianna Bronk @mdandersonnews hubs.li/Q03qZCgB0

🚨 Hope on the Horizon for KIT-Driven Cancers HT-KIT, an investigational gene-silencing therapy, is showing results in early studies for GIST, with over 80% reduction in KIT gene expression. #MedEd #MedTwitter #RareCancer 👉 Learn more here: hubs.li/Q03qXnBz0